Stifel Upgrades Nektar Therapeutics (NKTR) to Buy on More Bullishness on Bempeg in Lung Cancer
Tweet Send to a Friend
(Updated - June 28, 2021 2:12 AM EDT)Stifel analyst Benjamin Burnett upgraded Nektar Therapeutics (NASDAQ: NKTR) from Hold to Buy ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
